H. Pylori infection. Other specified bacterial agents as the cause of diseases classified to other chapters
Conditions
Interventions
Intervention 1: Intrvention group: seqential treatment:Pantoprazole (40mg BD) Amoxicillin (if clearances of cratinin is between 3-10 mg/dl 250-500 mg BD and if it is lower 10mg/dl 250-500 mg Daily, (f
Treatment - Drugs
Intrvention group: seqential treatment:Pantoprazole (40mg BD) Amoxicillin (if clearances of cratinin is between 3-10 mg/dl 250-500 mg BD and if it is lower 10mg/dl 250-500 mg Daily, (for the first fiv
Control group: Standard regimen: Amoxicillin (if clearances of cratinine is between 3-10 mg/dl 250-500 mg BD and if it is lower 10mg/dl 250-500 mg Daily), Pantoprazole (40 mg BD) and Claithromycin (25
Sponsors
Mazandaran University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age more than 18 years, dyspepsia during last month and positive H.pylori infection (positive rapid urease test and positive biopsy by endoscope). Exclusion criteria: Antibiotic therapy for eradication of H.pylori, consumption of Proton Pump Inhibitor, H2 blockers, Bismuth, or NSAIDS during last month, consumption of anticoagulants, Ketoconazol or corticosteroids, history of gastric or esophageal surgery, hypersensitivity to antibiotics, negative biopsy of GI, smoking or alcohol use, pregnancy, lactation, severe heart diseases (MI, EF = 30), liver & thyroid diseases and malignancy.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication of H. Pylori infection. Timepoint: 3 month after treatment. Method of measurement: Stool antigen test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAtieh Makhlough
Mazandaran Univercity of Medical Sciences and Health Services
Outcome results
None listed